Prestige Biopharma(Prestige Biopharma)和阿根廷的Biosidus(Biosidus)将在拉丁美洲出售价格低廉的图兹努埃(Tuznue)生物类相似的图兹努埃(Tuznue)产品。 Prestige Biopharma and Argentina’s Biosidus will sell affordable Tuznue® biosimilar in Latin America.

Prestige Biopharma与阿根廷的Biosidus合作, 将Tuznue(trastuzumab)商业化, 这与阿根廷、墨西哥、玻利维亚和巴拉圭的Herceptin相似。 Prestige Biopharma has partnered with Argentina’s Biosidus to commercialize Tuznue® (trastuzumab), a biosimilar to Herceptin, in Argentina, Mexico, Bolivia, and Paraguay. 在布宜诺斯艾利斯,Biosidus公司将使用Prestige公司从其新加坡设施供应的药物在布宜诺斯艾利斯制造欧洲联盟批准的用于HER2-呈阳性的乳癌和胃癌的药物。 The European Union-approved drug, used for HER2-positive breast and gastric cancers, will be manufactured in Buenos Aires by Biosidus using drug substance supplied by Prestige from its Singapore facility. 该协定旨在扩大拉丁美洲各地获得负担得起的、高质量的生物类同治疗的机会。 The agreement aims to expand access to affordable, high-quality biosimilar treatments across Latin America.